FGFR4 and breast cancer: Bange et al [32] and Morimoto et al [33] have demonstrated that the Arg388 allele of FGFR4 polymorphism in the transmembrane domain is associated with poor prognosis in breast cancer, colon cancer and high-grade soft-tissue sarcoma, respectively.